“ I’m very satisfied with the chemistry work at Aurigene, collaborated both chemistry (FTE) and biology (FFS). Technical discussion, weekly updates and meetings were good.”
Testimonial By Biotech, US
“Aurigene is very flexible in allocating FTEs and shipping compounds to the preferred destination. Updates on raw material, reports and LNBs are remarkable. Quick turn around time for solving problems using analytical techniques.”
Testimonial By Large Pharma, APAC
“Based on the FFS experience with Aurigene, it increased the bandwidth from FFS to FTE business. The level of communication and transparency in communication was excellent. Project reports and weekly updates are prepared well and on time. ”
Testimonial By Biotech, US
“Based on the pilot peptide program, we extended an FTE collaboration with Aurigene. The scientific team was excellent in communication and problem-solving. The management was proactive and ready to invest in capability and capacity building.”
Testimonial By Large pharma, US
“Happy with the quality of product, productivity and problem-solving capacity. Proactive communication about shipments helped us to plan our studies efficiently. Aurigene is a one-stop-shop for our discovery and development needs.”
Testimonial By Large pharma, EU
“Happy with the scientific team, hence restarted research collaboration. The team is very responsible, trustable, and reliable. All discovery services are under one roof.”
Testimonial By Biotech, USAurigene Pharmaceutical Services is
a leading CDMO/CRO
that provides contact research and manufacturing services
Contact NowResources
Oligonucleotide as a novel class of therapeutic modality
JULY 02, 2021
The influence of formulation development and its route of administration
JANUARY 04, 2021
Biologics Process Development Services
Physiochemical Characterization Services
cGMP Development and Manufacturing Services
Technology meets sustainability - How a complex API development process goes green
Accelerating Drug Discovery Through Innovative Partnerships
Evolution in Pharma Industry and Demand for Integrated CDMO
Peptide Development and Manufacturing
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
Simple and efficient synthesis of imidazoquinoxalines and spiroquinoxalinones via pictect-spengler reaction using Wang resin, Synthetic Communications
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.